{
  "abstract": "ObjectiveExtranodal spread is an adverse prognostic factor in several cancers. In clinically early-stage cervical cancer and positive lymph nodes after radical hysterectomy, extranodal spread is routinely registered in pathology reports, but it does not influence adjuvant treatment decisions. This nationwide study assessed the prognostic value of extranodal spread.\n\nMethodsPatients diagnosed between 2009 and 2024 with clinical early-stage cervical cancer (TNM T1 to T2a2) and pathologically positive regional lymph nodes after radical hysterectomy were identified from the Netherlands Cancer Registry. Cox proportional-hazard models assessed differences in overall survival and recurrence-free survival. A Bayesian Cox model with informative prior was applied to complement overall survival analysis. Recurrence patterns were compared by extranodal spread status.\n\nResultsAmong 408 patients, 46 (11.3%) had extranodal spread. In multivariable frequentist analysis, extranodal spread was significantly associated with poorer recurrence-free survival (hazard ratio [HR] 1.97, 95% confidence interval [CI] 1.11-3.49), but not with overall survival (HR 1.37, CI 0.78-2.41). Bayesian analysis showed a significant difference in overall survival (HR 1.63, CI 1.14-2.27). Among patients with recurrence, the distribution of locoregional and distant recurrence patterns did not significantly differ between those with and without extranodal spread (p=0.09).\n\nConclusionExtranodal spread is associated with poorer recurrence-free survival in clinically early-stage cervical cancer treated with radical hysterectomy. For overall survival, results were directionally consistent but dependent on the analytical approach, likely reflecting limited statistical power. These findings suggest a role for extranodal spread in risk stratification and follow-up, warranting further investigation before informing treatment decisions.\n\nDisclosuresThe authors have no conflicts of interest to disclose.\n\nKey messagesO_ST_ABSWhat is already known on this topicC_ST_ABSExtranodal spread is an established adverse prognostic factor in several malignancies. In clinically early-stage cervical cancer treated with radical hysterectomy, extranodal spread is routinely reported when lymph nodes are positive, although it does not currently influence adjuvant treatment decisions.\n\nWhat this study addsIn this nationwide cohort of patients with clinically early-stage cervical cancer treated with radical hysterectomy, extranodal spread was associated with poorer recurrence-free survival. For overall survival, estimates consistently suggested worse outcomes in patients with extranodal spread, although statistical significance depended on the analytical approach.\n\nHow this study might affect research, practice or policyThese findings suggest that extranodal spread may be a clinically relevant prognostic marker in clinically early-stage cervical cancer and could contribute to improved risk stratification, follow-up strategies, and future evaluation of adjuvant treatment guidelines.",
  "abstract_shown": true,
  "affiliations": [
    "Netherlands Comprehensive Cancer Organisation"
  ],
  "article_type": "PUBLISHAHEADOFPRINT",
  "arxiv": null,
  "author_total": 6,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "R. G. F. M. van der Ven"
    },
    {
      "name": "H. H. Wenzel"
    },
    {
      "name": "M. A. van der Aa"
    },
    {
      "name": "C. H. Mom"
    },
    {
      "name": "N. B. Thuijs"
    },
    {
      "name": "J. van der Velden"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/964znzpbwgex5.bib",
  "cited_by": 0,
  "doi": "10.64898/2026.09.02.26362042",
  "fulltext_url": "https://www.medrxiv.org/content/10.64898/2026.09.02.26362042v1.full",
  "id": "964znzpbwgex5",
  "issns": [],
  "landing_url": "https://www.medrxiv.org/content/10.64898/2026.09.02.26362042v1",
  "language": null,
  "licence": "CC-BY-NC-ND",
  "licence_label": "CC BY-NC-ND",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "medrxiv",
      "oncology"
    ],
    [
      "openalex",
      "2729|Endometrial and Cervical Cancer Treatments"
    ]
  ],
  "openalex": "W7211916950",
  "pdf_url": "https://www.medrxiv.org/content/10.64898/2026.09.02.26362042v1.full.pdf",
  "pmcid": null,
  "pmid": null,
  "published": "2026-09-02",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/964znzpbwgex5.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:17:51Z",
      "native_id": "10.64898/2026.09.02.26362042",
      "source": "medrxiv",
      "url": "https://www.medrxiv.org/content/10.64898/2026.09.02.26362042v1"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "medrxiv:oncology",
      "subfield": "oncology"
    }
  ],
  "title": "The impact of extranodal spread on overall and recurrence-free survival in patients with clinically early-stage cervical cancer, but with tumor positive pelvic lymph nodes after radical hysterectomy",
  "title_text": "The impact of extranodal spread on overall and recurrence-free survival in patients with clinically early-stage cervical cancer, but with tumor positive pelvic lymph nodes after radical hysterectomy",
  "type": "preprint",
  "updated_at": "2026-10-30T12:17:51Z",
  "url": "https://research.draconitic.com/paper/964znzpbwgex5",
  "venue": "medRxiv",
  "versions": []
}